[go: up one dir, main page]

WO2007079317A3 - Utilisation d’hypno-sedatifs pour traiter l’obesite ou maintenir la perte de poids - Google Patents

Utilisation d’hypno-sedatifs pour traiter l’obesite ou maintenir la perte de poids Download PDF

Info

Publication number
WO2007079317A3
WO2007079317A3 PCT/US2006/061679 US2006061679W WO2007079317A3 WO 2007079317 A3 WO2007079317 A3 WO 2007079317A3 US 2006061679 W US2006061679 W US 2006061679W WO 2007079317 A3 WO2007079317 A3 WO 2007079317A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating obesity
weight loss
maintaining weight
sedative hypnotics
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/061679
Other languages
English (en)
Other versions
WO2007079317A2 (fr
Inventor
Phillip B Chappell
David C Gruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of WO2007079317A2 publication Critical patent/WO2007079317A2/fr
Publication of WO2007079317A3 publication Critical patent/WO2007079317A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention concerne un procédé et des thérapies associées pour traiter l’obésité ou un trouble de l’alimentation associé en administrant un composé actif du récepteur GABA-A, tel qu’un hypno-sédatif, seul ou en combinaison avec un autre hypno-sédatif ou un agent anti-obésité. Spécifiquement, l’invention concerne un procédé pour traité l’obésité ou un trouble de l’alimentation associé en administrant de l’indiplon.
PCT/US2006/061679 2005-12-06 2006-12-06 Utilisation d’hypno-sedatifs pour traiter l’obesite ou maintenir la perte de poids Ceased WO2007079317A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74275105P 2005-12-06 2005-12-06
US60/742,751 2005-12-06

Publications (2)

Publication Number Publication Date
WO2007079317A2 WO2007079317A2 (fr) 2007-07-12
WO2007079317A3 true WO2007079317A3 (fr) 2007-09-07

Family

ID=38141425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/061679 Ceased WO2007079317A2 (fr) 2005-12-06 2006-12-06 Utilisation d’hypno-sedatifs pour traiter l’obesite ou maintenir la perte de poids

Country Status (1)

Country Link
WO (1) WO2007079317A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066919A1 (fr) * 1998-06-19 1999-12-29 Mcneil-Ppc, Inc. Preparation pharmaceutique contenant un sel d'acetaminophene et au moins un autre principe actif
US20050182268A1 (en) * 2004-02-13 2005-08-18 Jean-Claude Souvie Process for the synthesis of (7-methoxy-3, 4-dihydro-1-naphthalenyl) acetonitrile and its application in the synthesis of agomelatine
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
FR2869542A1 (fr) * 2004-04-29 2005-11-04 Marie Madeleine Jeannet Gagnon Traitement medical destine a faciliter la perte de poids et l'affinement localise (communement appele "cellulite")
WO2006105455A2 (fr) * 2005-03-31 2006-10-05 Phase 2 Discovery Methodes de traitement utilisant certains derives de melatonine
WO2006133543A1 (fr) * 2005-06-17 2006-12-21 Everslim Formulations Ltd. Suppléments alimentaires pour perte de poids, énergie durant la journée et relaxation la nuit

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066919A1 (fr) * 1998-06-19 1999-12-29 Mcneil-Ppc, Inc. Preparation pharmaceutique contenant un sel d'acetaminophene et au moins un autre principe actif
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US20050182268A1 (en) * 2004-02-13 2005-08-18 Jean-Claude Souvie Process for the synthesis of (7-methoxy-3, 4-dihydro-1-naphthalenyl) acetonitrile and its application in the synthesis of agomelatine
FR2869542A1 (fr) * 2004-04-29 2005-11-04 Marie Madeleine Jeannet Gagnon Traitement medical destine a faciliter la perte de poids et l'affinement localise (communement appele "cellulite")
WO2006105455A2 (fr) * 2005-03-31 2006-10-05 Phase 2 Discovery Methodes de traitement utilisant certains derives de melatonine
WO2006133543A1 (fr) * 2005-06-17 2006-12-21 Everslim Formulations Ltd. Suppléments alimentaires pour perte de poids, énergie durant la journée et relaxation la nuit

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FILE S E: "Effects of benzodiazepines and naloxone on food intake and food preference in the rat", APPETITE 1980 UNITED KINGDOM, vol. 1, no. 3, 1980, pages 215 - 224, XP009085582 *
GADDE KISHORE M ET AL: "Bupropion treatment of olanzapine-associated weight gain - An open-label, prospective trial", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 26, no. 4, August 2006 (2006-08-01), pages 409 - 413, XP009085605, ISSN: 0271-0749 *
GRIMM V E ET AL: "THE EFFECTS OF CHRONIC DIAZEPAM TREATMENT ON BODY WEIGHT AND FOOD INTAKE IN RATS", INTERNATIONAL JOURNAL OF NEUROSCIENCE, vol. 18, no. 1-2, 1983, pages 127 - 136, XP009085584, ISSN: 0020-7454 *
MCLAUGHLIN C ET AL: "CHOLECYSTOKININ AMPHETAMINE AND DIAZEPAM AND FEEDING IN LEAN AND OBESE ZUCKER RATS", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 10, no. 1, 1979, pages 87 - 94, XP002438687, ISSN: 0091-3057 *
TEWS J K: "DIETARY GABA DECREASES BODY WEIGHT OF GENETICALLY OBESE MICE", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 29, no. 24, 14 December 1981 (1981-12-14), pages 2535 - 2542, XP001098279, ISSN: 0024-3205 *
YUTRZENKA G J ET AL: "Substitution of temazepam and midazolam in pentobarbital-dependent rats.", PHYSIOLOGY & BEHAVIOR JUL 1989, vol. 46, no. 1, July 1989 (1989-07-01), pages 55 - 60, XP002438686, ISSN: 0031-9384 *

Also Published As

Publication number Publication date
WO2007079317A2 (fr) 2007-07-12

Similar Documents

Publication Publication Date Title
WO2007061874A3 (fr) Procedes et compositions utilises dans le traitement du cancer
WO2006083971A3 (fr) Anticorps dr5 et utilisations de ceux-ci
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2009020802A3 (fr) Traitement de l'obésité
WO2008150530A3 (fr) Molécules de liaison de cripto
WO2007011962A3 (fr) Traitement du cancer
WO2008030883A3 (fr) Traitement du cancer
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2009043051A3 (fr) Molécules se fixant au cd23 et leurs méthodes d'utilisation
IL186458A0 (en) Skin enrichment using coq10 as the delivery system
WO2007064945A3 (fr) Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies
WO2008003007A3 (fr) Compositions et procédés destinés au traitement d'infections parasitaires
WO2006077471A3 (fr) Therapies combinees ciblant de multiples recepteurs toll, et leur utilisation
WO2007146414A3 (fr) Thérapie combinée utilisant des molécules de liaison au récepteur de la lymphotoxine bêta associées avec d'autres agents
WO2007143086A3 (fr) Procédé d'administration
WO2007059202A3 (fr) Derives de pyrazolyluree utilisables dans le traitement du cancer
WO2009150255A3 (fr) Marqueurs destinés à prédire la réponse et la survie de patients traités anti-egfr
ZA200903837B (en) Use of 3-Alpha-androstanediol, optionally in combination with A-5-HT1A agonist, in the treatment of sexual dysfunction
WO2008010991A3 (fr) Méthodes et compositions pour le traitement du cancer
WO2009158374A3 (fr) Inhibiteurs d’activité akt
WO2007110384A3 (fr) Tube rempli d'une mousse a cellules ouvertes de resine de melamine/formaldehye et son utilisation en tant que filtre ou melangeur statique
IL206767A0 (en) B cell depleting antibodies, or fragments thereof, compositions comprising the same and use thereof for treating chronic fatigue syndrome
WO2007022385A3 (fr) Molécules se liant au cxcr4
WO2007106915A3 (fr) Anticorps à efgl 7 et leurs procédés d'utilisation
WO2009009034A3 (fr) Procédées et compositions utiles dans le traitement de la mucosite

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06849007

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06849007

Country of ref document: EP

Kind code of ref document: A2